Published by Josh White on 26th June 2026
(Sharecast News) - Crism Therapeutics reported a wider full-year loss on Friday, reflecting increased investment in clinical and pre-clinical development as it prepared to start a Phase 2 trial of irinotecan-ChemoSeed in glioblastoma.
URL: http://www.digitallook.com/dl/news/story/36034033/...